Kalaris Therapeutics's market cap is currently $77.50M. The company's EPS TTM is $-11.751; its P/E ratio is ―; Kalaris Therapeutics is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
